These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11641444)

  • 21. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura.
    Bierling P; Godeau B
    Hum Immunol; 2005 Apr; 66(4):387-94. PubMed ID: 15866702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective mechanisms of IVIG.
    Clynes R
    Curr Opin Immunol; 2007 Dec; 19(6):646-51. PubMed ID: 18032008
    [No Abstract]   [Full Text] [Related]  

  • 23. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells.
    Bazin R; Lemieux R; Tremblay T; St-Amour I
    Br J Haematol; 2004 Oct; 127(1):90-6. PubMed ID: 15384982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of IVIG action in immune thrombocytopenic purpura.
    Hansen RJ; Balthasar JP
    Clin Lab; 2004; 50(3-4):133-40. PubMed ID: 15074465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Putative mechanisms of the effect of intravenous gamma-globulin.
    Rosen FS
    Clin Immunol Immunopathol; 1993 Jun; 67(3 Pt 2):S41-3. PubMed ID: 8500280
    [No Abstract]   [Full Text] [Related]  

  • 26. Immune thrombocytopenia purpura.
    Hunt CW
    Medsurg Nurs; 2010; 19(4):237-9. PubMed ID: 20860250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternatives to intravenous immunoglobulins in the treatment of immune thrombocytopenic purpura.
    David M; Chevalier I
    Vox Sang; 2002 Aug; 83 Suppl 1():443-5. PubMed ID: 12617183
    [No Abstract]   [Full Text] [Related]  

  • 28. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells.
    Siragam V; Crow AR; Brinc D; Song S; Freedman J; Lazarus AH
    Nat Med; 2006 Jun; 12(6):688-92. PubMed ID: 16715090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Harmful and beneficial antibodies in immune thrombocytopenic purpura.
    Imbach PA
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):25-30. PubMed ID: 8033430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin or megadose methylprednisolone for the treatment of idiopathic thrombocytopenic purpura.
    Ozsoylu S
    Am J Pediatr Hematol Oncol; 1991; 13(3):364-5. PubMed ID: 1817495
    [No Abstract]   [Full Text] [Related]  

  • 31. Enhanced efficacy of anti-D immunoglobulin for treating ITP is not explained by higher immunoglobulin polymer content.
    Dolman C; Thorpe SJ; Thorpe R
    Biologicals; 2001 Jun; 29(2):75-9. PubMed ID: 11580212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of steroid and intravenous immunoglobulin on thrombopoietin levels in pediatric patients with immune thrombocytopenic purpura.
    Koçak U; Gürsel T; Oztürk G
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):121-5. PubMed ID: 10759004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High dose intravenous immunoglobulin repertoire versus anti-D. Disproportions in quantity and quality.
    Rewald E; Francischetti MM; Barberis L
    Cell Mol Biol (Noisy-le-grand); 2002 May; 48(3):265-9. PubMed ID: 12030430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia.
    Cooper N
    Hematol Oncol Clin North Am; 2009 Dec; 23(6):1317-27. PubMed ID: 19932436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of action of IVIg: physiology of Fc receptors.
    Reilly MP; McKenzie SE
    Vox Sang; 2002 Aug; 83 Suppl 1():57-63. PubMed ID: 12617105
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy.
    Duru F; Fisgin T; Yarali N; Kara A
    Pediatr Hematol Oncol; 2002 Jun; 19(4):219-25. PubMed ID: 12051587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins.
    Mehta YS; Badakere SS
    J Postgrad Med; 1996; 42(2):46-9. PubMed ID: 9715299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy.
    Binstadt BA; Geha RS; Bonilla FA
    J Allergy Clin Immunol; 2003 Apr; 111(4):697-703. PubMed ID: 12704346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of idiopathic thrombopenic purpura in adolescents by intravenous immunoglobulin].
    Rodríguez Cuartero A; González Martínez F
    An Med Interna; 1998 Dec; 15(12):675-6. PubMed ID: 9972611
    [No Abstract]   [Full Text] [Related]  

  • 40. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?
    Siragam V; Brinc D; Crow AR; Song S; Freedman J; Lazarus AH
    J Clin Invest; 2005 Jan; 115(1):155-60. PubMed ID: 15630455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.